These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38861249)

  • 1. Insights into the prognostic value and immunological role of CD74 in pan-cancer.
    Liu Z; Chen M; Zheng W; Yuan S; Zhao W
    Discov Oncol; 2024 Jun; 15(1):222. PubMed ID: 38861249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 3. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

  • 4. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
    Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
    Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
    Front Oncol; 2021; 11():607224. PubMed ID: 34026603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 10. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
    Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
    Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
    Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas.
    Xu S; Li X; Tang L; Liu Z; Yang K; Cheng Q
    Front Mol Biosci; 2021; 8():706949. PubMed ID: 34540893
    [No Abstract]   [Full Text] [Related]  

  • 13. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
    Fei Q; Zhang X; Wang S; Shu G; Yin G
    J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
    Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
    Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.